Current status of the development of intravesical drug delivery systems for the treatment of bladder cancer

Yoon, Ho Yub; Yang, Hee Mang; Kim, Chang‐Hyun; Goo, Yoon Tae; Kang, Myung Joo; Lee, Sang Kil; Choi, Young Wook

doi:10.1080/17425247.2020.1810016

Cited by 34 publications

(29 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, and based on our previous studies, we selected the protease bromelain (PB), to coat nanoparticles and provide them with higher stability. Interestingly, it was described that this protein has the capacity of crossing mucosal barriers, required for the envisaged local intravesical delivery [33]. As shown in Figure 4, we were able to coat the particles without significantly modifying their characteristics in most conditions.…”

Section: Modifying the Surface Of The Particles To Enhance Their Stabilitymentioning

confidence: 73%

Role of Survivin in Bladder Cancer: Issues to Be Overcome When Designing an Efficient Dual Nano-Therapy

et al. 2021

View full text Add to dashboard Cite

Bladder cancer is the 10th most diagnosed cancer, with almost 10 M cancer deaths last year worldwide. Currently, chemotherapy is widely used as adjuvant therapy after surgical transurethral resection. Paclitaxel (PTX) is one of the most promising drugs, but cancer cells acquire resistance, causing failure of this treatment and increasing the recurrence of the disease. This poor chemotherapeutic response has been associated with the overexpression of the protein survivin. In this work, we present a novel dual nano-treatment for bladder cancer based on the hypothesis that the inhibition of survivin in cancer cells, using a siRNA gene therapy strategy, could decrease their resistance to PTX. For this purpose, two different polymeric nanoparticles were developed to encapsulate PTX and survivin siRNA independently. PTX nanoparticles showed sizes around 150 nm, with a paclitaxel loading of around 1.5%, that produced sustained tumor cell death. In parallel, siRNA nanoparticles, with similar sizes and loading efficiency of around 100%, achieved the oligonucleotide transfection and knocking down of survivin expression that also resulted in tumor cell death. However, dual treatment did not show the synergistic effect expected. The root cause of this issue was found to be the cell cycle arrest produced by nuclear survivin silencing, which is incompatible with PTX action. Therefore, we concluded that although the vastly reported role of survivin in bladder cancer, its silencing does not sensitize cells to currently applied chemotherapies.

show abstract

Section: Modifying the Surface Of The Particles To Enhance Their Stabilitymentioning

confidence: 73%

Role of Survivin in Bladder Cancer: Issues to Be Overcome When Designing an Efficient Dual Nano-Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, the low permeability of intravesical drugs into the bladder wall is an obstacle for the ideal therapeutic effect [ 65 ]. Polymeric NPs are able to improve the permeability of intravesical drug and extend the dwell time due to their water-dispersible and mucoadhesive properties [ 66 ]. Another study load epirubicin with poly(ethyl-2-cyanoacrylate)(PECA) NPs and demonstrated that this system could provide sustained drug tissue concentrations and significant cytotoxicity in human BC cells [ 67 ].…”

Section: Bladder Cancer Treatment and Nanotechnologymentioning

confidence: 99%

Application of nanotechnology in the diagnosis and treatment of bladder cancer

Luo

Wang

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

Bladder cancer (BC) is a common malignancy in the genitourinary system and the current theranostic approaches are unsatisfactory. Sensitivity and specificity of current diagnosis methods are not ideal and high recurrence and progression rates after initial treatment indicate the urgent need for management improvements in clinic. Nanotechnology has been proposed as an effective method to improve theranosis efficiency for both non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). For example, gold nanoparticles (AuNPs) have been developed for simple, fast and sensitive urinary sample test for bladder cancer diagnosis. Nanoparticles targeting bladder cancers can facilitate to distinguish the normal and abnormal bladder tissues during cystoscopy and thus help with the complete removal of malignant lesions. Both intravenous and intravesical agents can be modified by nanotechnology for targeted delivery, high anti-tumor efficiency and excellent tolerability, exhibiting encouraging potential in bladder cancer treatment. Photosensitizers and biological agents can also be delivered by nanotechnology, intermediating phototherapy and targeted therapy. The management of bladder cancer remained almost unchanged for decades with unsatisfactory effect. However, it is likely to change with the fast-developed nanotechnology. Herein we summarized the current utility of nanotechnology in bladder cancer diagnosis and treatment, providing insights for the future designing and discovering novel nanoparticles for bladder cancer management. Graphical Abstract

show abstract

“…First-line treatment of non-muscle-invasive bladder cancer envisages surgical resection of the tumor followed by local instillations, repeated over time, of different chemotherapeutic agents ( e.g. epirubicin, mitomycin, Bacillus Calmette-Guérin) to prevent recurrence and progress into muscle-invasive bladder cancer ( Babjuk et al, 2019 ; Yoon et al, 2020 ).…”

Section: Pathology Of Urinary Bladdermentioning

confidence: 99%

“…A further issue involved in therapies based on intravesical administration of drugs, particularly those for bladder cancer, is given by the poor permeability of urothelium, which may represent a tough barrier to be crossed especially by molecules with high molecular weight ( Yoon et al, 2020 ).…”

Section: Administration Of Drugs Into the Bladder And Relevant Open Issuesmentioning

confidence: 99%

Intravesical drug delivery approaches for improved therapy of urinary bladder diseases

Palugan

Cerea

Cirilli

et al. 2021

International Journal of Pharmaceutics: X

View full text Add to dashboard Cite

Diseases of the urinary bladder have high incidence rates and burden healthcare costs. Their pharmacological treatment involves systemic and local drug administration. The latter is generally accomplished through instillation of liquid formulations and requires repeated or long-term catheterization that is associated with discomfort, inflammation and bacterial infections. Consequently, compliance issues and dropouts are frequently reported. Moreover, instilled drugs are progressively diluted as the urine volume increases and rapidly excreted. When penetration of drugs into the bladder wall is needed, the poor permeability of the urothelium has also to be accounted for. Therefore, much research effort is spent to overcome these hurdles, thereby improving the efficacy of available therapies. Particularly, indwelling delivery systems suited for i) insertion into the bladder through the urethra, ii) intra-organ retention and prolonged release for the desired time lapse, iii) final elimination, either spontaneous or by manual removal, have been proposed to reduce the number of catheterization procedures and reach higher drug levels at the target site. Vesical retention of such devices is allowed by the relevant expansion that can either be triggered from the outside or achieved exploiting elastic and purposely 4D printed shape memory materials. In this article, the main rationales and strategies for improved intravesical delivery are reviewed.

show abstract

Current status of the development of intravesical drug delivery systems for the treatment of bladder cancer

Cited by 34 publications

References 130 publications

Role of Survivin in Bladder Cancer: Issues to Be Overcome When Designing an Efficient Dual Nano-Therapy

Role of Survivin in Bladder Cancer: Issues to Be Overcome When Designing an Efficient Dual Nano-Therapy

Application of nanotechnology in the diagnosis and treatment of bladder cancer

Intravesical drug delivery approaches for improved therapy of urinary bladder diseases

Contact Info

Product

Resources

About